Understanding GLP-1s: A Guide for Medical Examiners Evaluating CMV Drivers: What rising prescriptions mean for driver safety and examiners’ vigilance

Diabetic Truck Driver

With the rising use of Glucagon-like Peptide-1 (GLP-1) receptor agonists in patients with Type 2 Diabetes Mellitus (T2DM) and obesity, certified medical examiners (CMEs) are increasingly likely to encounter commercial motor vehicle (CMV) drivers prescribed these medications. This blog explores the therapeutic role of GLP-1s, their potential side effects, and the implications for driver safety and medical certification.

Clinical Role of GLP-1 Receptor Agonists

GLP-1s are antidiabetic agents used to:

• Improve glycemic control in T2DM as an adjunct to diet and exercise.

• Support weight loss in patients with obesity, including those with obstructive sleep apnea (OSA).

• Reduce cardiovascular risk (e.g., myocardial infarction, stroke, cardiovascular death) in adults with T2DM and established cardiovascular disease.

• Slow the decline in estimated glomerular filtration rate (eGFR) in patients with T2DM and chronic kidney disease (CKD), potentially delaying progression to end-stage renal disease.

Common GLP-1 Agents

Medication Indications
Byetta (Exenatide) T2DM; less commonly used today
Ozempic / Wegovy (Semaglutide) T2DM, Obesity
Mounjaro / Zepbound (Tirzepatide) T2DM, Obesity, OSA
Saxenda / Victoza (Liraglutide) Saxenda: Obesity; Victoza: T2DM and Cardiovascular risk reduction
 

Zepbound, in particular, may benefit drivers with moderate-to-severe OSA and obesity, as weight loss can improve sleep apnea symptoms and metabolic rate.

Adverse Effects and Safety Concerns

GLP-1s are generally well tolerated, but potential side effects include:
• Gastrointestinal issues: nausea, vomiting, diarrhea, abdominal pain, dyspepsia
• Gallstones (cholelithiasis), sometimes requiring cholecystectomy
• Muscle wasting, weight loss, hair loss
• Post-marketing reports: acute pancreatitis, necrotizing pancreatitis, acute kidney injury, dizziness, and rare fatalities.
 Dehydration and Hypotension
 Severe hypoglycemia—especially when combined with other antidiabetic agents

Black Box Warning

GLP-1s carry a warning for potential thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). They are contraindicated in individuals with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2. In January 2024, the FDA also reviewed reports of suicidal ideation and behavior associated with these agents.

Certified Medical Examiner (CME) Guidance

When evaluating a CMV driver prescribed GLP-1s, CMEs can consider the following:

• Obtain a thorough medical history: Confirm the diagnosis (T2DM, obesity, OSA), medication regimen, and any side effects that may impair safe driving.

• Conduct a comprehensive physical exam: Assess for comorbidities such as cardiovascular disease, retinopathy, renal disease, or neuropathy that may disqualify the driver.

• Request medical clearance: The treating provider should confirm the diagnosis, dosage, and safety of treatment, and understand the physical and mental demands of CMV operation.

• Use FMCSA Form MCSA-5895 (optional): This form can help document provider clearance for medications of concern.

• Educate the driver: Emphasize hydration to reduce the risk of acute kidney injury and monitor for rapid weight loss, which may cause hypoglycemia or hypotension.

• Review labs if needed: While not required, CMEs may request metabolic panels and HbA1c levels to assess stability and safety.

As the use of GLP-1 receptor agonists continues to expand, certified medical examiners must remain vigilant, informed, and compassionate in their evaluations. These medications offer powerful benefits for managing chronic conditions, but they also carry risks that can directly impact a driver’s ability to operate a CMV safely.

By combining thorough clinical assessment with thoughtful collaboration between examiners and treating providers, we can uphold both public safety and patient dignity assuring that every driver is evaluated with care, respect, and evidence-based insight.

References: https://emedicine.medscape.com/article/123702-overview

Upcoming Compliance Changes for NRII: What You Need to Know

NRII Implementation Deadline

The Federal Motor Carrier Safety Administration (FMCSA) has set June 23, 2025, as the official compliance date for the National Registry Integration Initiative (NRII). However, states may implement NRII earlier if they are prepared. Once a state integrates NRII, medical certification information for Commercial Learner's Permit (CLP) applicants and Commercial Driver’s License (CDL) holders will be electronically transmitted from the National Registry to the State Driver Licensing Agency (SDLA). In such states, the paper Medical Examiner’s Certificate (MCSA-5876) may no longer serve as valid proof of medical certification.

Key Changes Effective June 23, 2025

Several important modifications will take place:

• FMCSA will electronically transmit medical examination results (qualified, unqualified, and voided) for CLP applicants and CDL holders to the SDLAs.
• FMCSA will transmit medical variance information (medical exemptions and Skill Performance Evaluation (SPE) certificates) electronically to the SDLAs.
• SDLAs will update CDL Information System (CDLIS) driver Motor Vehicle Records (MVR) with examination results and restrictions.
• Medical examiners will no longer issue paper certificates (MCSA-5876) to CLP applicants or CDL holders.
• CLP applicants and CDL holders will no longer need to submit paper certificates to their SDLAs.
• Motor carriers must verify medical certification electronically through the CDLIS driver MVR instead of using paper Medical Examiner’s Certificates.

Medical Variances

If a medical examiner determines that a driver requires a medical variance, such as an SPE Certificate or medical exemption, the driver’s examination results will not be transmitted to the SDLA until FMCSA issues the variance. Once obtained, the National Registry system will link the variance with the original examination results and transmit them to the SDLA. Despite electronic transmission, drivers must still carry proof of medical variances while operating.

Ensuring Your Medical Certification is Posted to Your Record

Since drivers do not have direct access to the National Registry or SDLA systems, errors in transmission may occur. If a driver receives a CDL downgrade letter despite having completed a physical qualification exam, their medical certification was not received by the SDLA. Follow these steps to resolve the issue:

1. Contact the medical examiner who conducted your exam and ask them to verify if an error message was received regarding your certification.
2. Contact your SDLA to confirm whether the corrected medical certification was posted.
3. If the issue persists, reach out to FMCSA’s National Registry Technical Support Helpdesk at This email address is being protected from spambots. You need JavaScript enabled to view it. or (617) 494-3003.
If stopped by law enforcement and informed that you are not medically certified, follow the same steps immediately to correct the issue.

Non-CDL Holders

If you do not hold a CDL, NRII does not apply to you. Medical examiners will continue to issue the paper Medical Examiner’s Certificate (MCSA-5876) as proof of medical certification, and you must carry it while operating a commercial motor vehicle. However, if you later obtain a CDL, the SDLA can retrieve your existing certification information from the National Registry and post it to your CDLIS driver MVR.

Critical Updates to 49 CFR 391.49-SPE Certificate Program: What Certified Medical Examiners Need to Know!

On November 18, 2024, FMCSA published the attached technical amendment final rule that amends 49 CFR 391.49(d)(3)(i)(B) and (d)(3)(ii)(C) to clarify the meaning and effect of the current requirement that individuals with upper limb loss or impairment must be capable of demonstrating precision prehension and power grasp prehension to be eligible for a skill performance evaluation (SPE) certificate issued by FMCSA. The amendments clarify that a functioning hand is necessary to demonstrate precision prehension and power grasp prehension and that a prosthesis is required if the applicant does not have a hand. The amendments also clarify when an applicant has upper limb impairment that a prosthesis or orthotic device is required if the applicant is not capable of demonstrating precision prehension and power grasp prehension with each hand separately without a prosthesis or orthotic device.

Specifically, paragraphs (B) (for limb loss) and (C) (for limb impairment) relating to the statements made by the physiatrists and orthopedic surgeons in the medical evaluation summary have been amended to read as follows:

(B) A statement by the examiner that the applicant is capable of demonstrating precision prehension (e.g., grasping and manipulating knobs and switches using the fingers/thumb) and power grasp prehension (e.g., grasping, holding, and maneuvering the steering wheel using a hand) with each hand separately. Prior to applying for an SPE certificate, an applicant with loss of a hand or arm must be fitted and proficient with a proper prosthesis that enables the applicant to demonstrate precision prehension and power grasp prehension with each hand separately. This requirement does not apply to an individual who was granted a waiver, absent a prosthetic device, prior to January 6, 1986, the effective date of the requirement.

(C) A statement by the examiner that the applicant is capable of demonstrating precision prehension (e.g., grasping and manipulating knobs and switches using the fingers/thumb) and power grasp prehension (e.g., grasping, holding, and maneuvering the steering wheel using a hand) with each hand separately. Prior to applying for an SPE certificate, an applicant with upper limb impairment must be fitted and proficient with a proper prosthesis or orthotic device, if the applicant is not capable of demonstrating precision prehension and power grasp prehension with each hand separately without a prosthesis or orthotic device. This requirement does not apply to an individual who was granted a waiver, absent an orthotic device, prior to January 6, 1986, the effective date of the requirement.

In addition to the attached technical amendment final rule, FMCSA has also attached information outlining prevalent issues present when MEs are documenting evaluation outcomes of limb loss and impairment under 49 CFR 391.41(b)(1) and (2) during the physical qualification examination. These errors require FMCSA to void the examinations and require the drivers to obtain a new examination. FMCSA requests that all MEs review this information closely to ensure that examinations are recorded in accordance with the Federal Motor Carrier Safety Regulations.

Alternative Physical Qualification Standards for the Loss or Impairment of Limbs

Skill Performance Evaluation (SPE) Certificate Issues

 

 

Don't miss our latest NRCME Training updates! Connect with us.

Instagram NRCMEtraining Facebook-icon Twitter-icon Linked-In-icon